Arabinofuranosyluracil: A pyrimidine nucleoside formed in the body by the deamination of CYTARABINE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 18323 |
| CHEMBL ID | 1092065 |
| CHEBI ID | 68346 |
| SCHEMBL ID | 359587 |
| MeSH ID | M0001641 |
| PubMed CID | 12219138 |
| SCHEMBL ID | 360394 |
| MeSH ID | M0001641 |
| Synonym |
|---|
| spongouridine |
| arauridine |
| uracil arabinoside |
| uracil 1-beta-d-arabinofuranoside, lymphoma antiproliferative |
| 1beta-d-arabinofuranosyluracil |
| 1-beta-d-arabinofurnosyluracil |
| uracil, 1-beta-d-arabinofuranosyl- |
| ara-u |
| 1-beta-d-arabinofuranosyluracil |
| uridine arabinoside |
| nsc 68928 |
| brn 0028749 |
| spongouridine (van) |
| uracil, 1-beta-d-arabinofuranosyl- (van) |
| einecs 221-386-9 |
| uracil-beta-d-arabinofuranoside |
| 1-beta-d-arabinofuranosyl-(1h,3h)-pyrimidine-2,4-dione |
| chebi:68346 , |
| CHEMBL1092065 |
| unii-zk0wmw5nqf |
| zk0wmw5nqf , |
| 5-24-06-00136 (beilstein handbook reference) |
| 1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]pyrimidine-2,4-dione |
| 1-[(2r,3s,4s,5r)-5-(hydroxymethyl)-3,4-bis(oxidanyl)oxolan-2-yl]pyrimidine-2,4-dione |
| A820641 |
| AKOS015969693 |
| uracil 1-|a-d-arabinofuranoside |
| S4807 |
| 1-((2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione |
| 1-| cent-d-arabinofuranosyluracil |
| HG1013 |
| DRTQHJPVMGBUCF-CCXZUQQUSA-N |
| 1-(beta-d-arabinofuranosyl)uracil |
| 1-(beta-d-arabinofuranosyl)-pyrimidin-2,4(3h)-dione |
| uracil-1-beta-d-arabinofuranoside |
| J-700006 |
| SCHEMBL359587 |
| 1-?-d-arabinofuranosyluracil |
| DTXSID80184832 |
| uracil arabinoside, united states pharmacopeia (usp) reference standard |
| 2,4(1h,3h)-pyrimidinedione, 1-.beta.-d-arabinofuranosyl- |
| uracil arabinoside, european pharmacopoeia (ep) reference standard |
| 1-beta-d-arabinofuranosylpyrimidine-2,4(1h,3h)-dione (uracil arabinoside) |
| SW220050-1 |
| Q27136843 |
| DS-14592 |
| uracil 1-b-d-arabinofuranoside |
| BCP29295 |
| CS-0083204 |
| HY-N6652 |
| CCG-266899 |
| uracil arabinoside [usp-rs] |
| 1-.beta.-d-arabinofuranosyl-2,4(1h,3h)-pyrimidinedione |
| uracil 1--d-arabinofuranoside |
| 1-eta--rabinofuranosyluracl |
| uracil 1- beta -d-arabinofuranoside |
| arabinofuranosyluracil |
| AKOS015896937 |
| SCHEMBL360394 |
| 1-[(3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rectal bioavailability of Ara-C (serum AUC 4 h: 65 micrograms h-1 ml-1) administered in a suppository formulation containing tetrahydrouridine (a deamination inhibitor) and sodium salicylate (an adjuvant) to dogs was better than that from a suppository formulation without tetrahydrouridine (serum AUC 4 h: 18 micrograms h-1 ml-1)." | ( Enhanced serum concentrations of Ara-C using suppositories containing tetrahydrouridine as a deamination inhibitor of Ara-C. Engle, KK; Higuchi, T; Liversidge, GG; Nishihata, T, 1986) | 0.27 |
| " The bioavailability and disposition of 882C87, an anti-varicella zoster virus (VZV) agent, have been investigated in healthy young and elderly volunteers." | ( The bioavailability and disposition of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent. Jackson, SH; Lee, DR; Peck, RW; Posner, J; Wootton, R, 1995) | 0.29 |
| " The first approach was directed towards improving the bioavailability of acyclovir by examining the potential of a variety of prodrugs, leading to the new compound valaciclovir hydrochloride." | ( Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. Beauchamp, LM; Darby, G; de Miranda, P; Ertl, P; Krenitsky, TA; Lacey, S; Powell, KL; Purifoy, DJ; Rahim, SG; Roberts, G, 1993) | 0.29 |
| " One might question, as these data unfold, the relative value of drugs with such enhanced in vitro activity and oral bioavailability as compared with standard therapeutic agents." | ( Sorivudine: a promising drug for the treatment of varicella-zoster virus infection. Whitley, RJ, 1995) | 0.29 |
| " One might question, as these data unfold, the relative clinical value of antivirals with such enhanced in vitro activity and oral bioavailability as compared to standard compounds." | ( Sorivudine: a potent inhibitor of varicella zoster virus replication. Whitley, RJ, 1996) | 0.29 |
| " The objective of this study was to characterize the bioavailability and pattern of L-FMAU absorption using a pharmacokinetic model which incorporated two separate absorption processes following oral administration of the nucleoside in an animal model, the rat." | ( Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil (L-FMAU) in rats. Boudinot, FD; Chu, CK; Ma, T; Wright, JD, 1996) | 0.29 |
| " Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy." | ( New therapeutic approaches to the alphaherpesvirus infections. Cassady, KA; Whitley, RJ, 1997) | 0.3 |
| " Absorption of L-FMAU after oral administration was incomplete, and bioavailability was approximately 20%." | ( Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil in woodchucks. Ascenzi, MA; Baldwin, BH; Boudinot, FD; Chu, CK; Du, JF; Tennant, BC; Witcher, JW, 1997) | 0.3 |
| " This selection is usually based on pilot toxicity and general pharmacology studies in rodent and non-rodent animals, together with supporting comparative drug disposition studies to determine bioavailability and metabolic profile." | ( Importance of species selection in drug toxicity testing. Morton, DM, 1998) | 0.3 |
| " L-FMAU also has respectable bioavailability in rats." | ( Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Boudinot, FD; Cheng, YC; Choi, Y; Chu, CK; Cote, PJ; Gerin, JL; Hong, JH; Korba, BE; Peek, SF; Tennant, BC, 1998) | 0.3 |
| " This appears to be the result of improved metabolic bioavailability of cytoplasmically retargeted mutant HSV1-tk/GFP enzymes for reaction with the radiolabeled probe (e." | ( Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging. Ageyeva, L; Balatoni, J; Beresten, T; Blasberg, R; Doubrovin, M; Ponomarev, V; Serganova, I; Shavrin, A; Tjuvajev, JG; Vider, J, ) | 0.13 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The ascending dosage studies have been analyzed by the BV-araU RIA, and results indicate that the values of area under the serum concentration-time curve increased proportionally with the administered dose of BV-araU up to 80 mg." | ( A radioimmunoassay for the new antiviral agent 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Jagoda, E; Mantha, S; Ogan, M; Stouffer, B; Tsay, HM; Tu, JI; Turabi, N; Yost, F, 1992) | 0.28 |
| "6 microM at 6 h after dosing are in the range of the effective antiviral concentration for FEAU." | ( Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil in mice and rats. Chiang, J; Chou, TC; Gloff, CA; Kong, XB; Tong, WP; Vidal, P, 1992) | 0.28 |
| " In the initial phase I trial neurotoxicity, characterized by extrapyramidal dysfunction, was found to be the dose-limiting toxic effect, and a dosage of 32 mg/m2/day for 5 days was suggested for phase II studies." | ( Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. Abbruzzese, JL; Castellanos, AM; Krakoff, IH; Legha, SS; Levy, JK; Raber, MN; Schmidt, S, 1989) | 0.28 |
| " In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg." | ( Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines. Hsiung, GD; Mayo, DR, 1984) | 0.27 |
| " There was a lag of at least 5 h after dosing with 882C87 before 5PU was detectable in plasma." | ( Pharmacokinetics and tolerability of single oral doses of 882C87, a potent, new anti-varicella-zoster virus agent, in healthy volunteers. Crome, P; Holdich, TA; Peck, RW; Posner, J; Weatherley, BC; Wootton, R, 1995) | 0.29 |
| " This new drug produces enhanced plasma levels of acyclovir following oral dosing, which will not only allow more convenient dosing for the treatment of herpes simplex virus and varicella zoster virus (VZV) infections, but also mean that valaciclovir has the potential for superior clinical efficacy over acyclovir." | ( Acyclovir--and beyond. Darby, G, 1994) | 0.29 |
| " However, E-5-(2-bromovinyl)uracil (BVU) is the major metabolite found after oral dosing in animals other than mice." | ( Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats. Ashida, N; Ijichi, K; Machida, H; Watanabe, Y, 1993) | 0.29 |
| "Netivudine dosing produces complete inhibition of plasma dihydropyrimidine dehydrogenase." | ( Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine. Callaghan, J; Crome, P; Fraser, I; Frick, L; Peck, R; Posner, J; Wiggs, R; Wootton, R, 1996) | 0.29 |
| " Thus, the disposition of L-FMAU was linear over the dosage of 10 to 50 mg/kg." | ( Pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats. Boudinot, FD; Chu, CK; Ma, T; Wright, JD, 1995) | 0.29 |
| "The pharmacokinetics of L-FMAU in rats were independent of dose over the dosage range of 10 to 50 mg/kg." | ( Pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats. Boudinot, FD; Chu, CK; Ma, T; Wright, JD, 1995) | 0.29 |
| " These findings suggest that netivudine dosage may need to be reduced in patients with severe renal failure, and confirm that formation of the 5 PU is independent of the elimination of netivudine from plasma." | ( Pharmacokinetics of netivudine, a potent anti-varicella zoster virus drug, in patients with renal impairment. Bidault, R; Chretien, P; Fillastre, JP; Gillotin, C; Godin, M; Legallicier, B; Peck, RW; Posner, J; Wooton, R, 1996) | 0.29 |
| " Much of the current antiviral research focuses on providing drugs with (i) improved oral bioavailability and pharmacokinetics which permit less frequent oral or topical dosing for suppressive treatment of herpes simplex virus (HSV) infections, (ii) different mechanisms of action for synergic effects in treating resistant HSV infections in the immunocompromised host and (iii) improved efficacy." | ( New therapeutic approaches to the alphaherpesvirus infections. Cassady, KA; Whitley, RJ, 1997) | 0.3 |
| " With the completion of the first efficacy trials for each of these agents it has become apparent that, whilst less frequent dosing can he accomplished, it is not easy to significantly improve on the efficacy of aciclovir." | ( Antiviral drugs in development for herpes zoster. Fiddian, AP, 1996) | 0.29 |
| " In one study, healthy volunteers received an initial, single dose followed, a week later, by repeat dosing for 9 1/2 days; in the other, patients with shingles were treated for 8 days and data were also recorded for rash resolution and pain duration and intensity." | ( Multiple dose netivudine, a potent anti-varicella zoster virus agent, in healthy elderly volunteers and patients with shingles. Bannister, B; Crome, P; Crooks, RJ; Mandal, BK; McKendrick, MW; Peck, RW; Wood, MJ, 1996) | 0.29 |
| " All of these rats died within 10 days, whereas rats given SRV or tegafur alone under the same dosage conditions showed no appreciable change over 20 days compared with controls." | ( A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Kato, A; Ogura, K; Okuda, H; Takubo, H; Watabe, T, 1998) | 0.3 |
| " L(-)I-OddU is the most potent anti-Epstein-Barr Virus (EBV) compound without cytotoxicity and animal toxicity upon long-term dosing which gives the pharmacological levels of the drug in plasma." | ( Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers. Cheng, YC, 2001) | 0.31 |
| " In the present study, we evaluated the safety and efficacy of clevudine 30 mg daily for 24 weeks and assessed the durability of antiviral response for 24 weeks after cessation of dosing in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (e-CHB)." | ( Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Byun, KS; Cho, M; Cho, SH; Choi, JY; Choi, SK; Chon, CY; Chung, YH; Han, BH; Han, JY; Hwang, JS; Hwang, SG; Jeong, SH; Kim, BI; Kim, DG; Kim, HC; Kim, JH; Kim, TH; Kim, YS; Koh, KC; Kweon, YO; Lee, HJ; Lee, HS; Lee, HY; Lee, KS; Lee, MS; Lee, YJ; Lee, YS; Park, JW; Ryu, SH; Um, SH; Yang, JM; Yoo, BC; Yoo, HW; Yoo, K, 2007) | 0.34 |
| "Clevudine appears to be a potent and tolerable (over 12 weeks) anti-viral and the optimal dosage appears to be 30 mg once daily." | ( Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Blum, MR; Hann, HW; Lau, GK; Leung, N; Lim, SG; Marcellin, P; Mommeja-Marin, H; Moxham, C; Rousseau, F; Snow, A; Sorbel, J; Trepo, C, 2008) | 0.35 |
| "These results are consistent with once daily CLV dosing currently being used in Phase III clinical studies." | ( Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes. Furman, PA; Murakami, E; Niu, C, 2008) | 0.35 |
| "To assess biodistribution and dosimetry, six subjects with suspected hip or knee PJI and six healthy subjects underwent serial PET/CT after being dosed with 74MBq (2mCi) [(124)I]FIAU intravenously (IV)." | ( [(124)I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection. Alavi, A; Barnett, TM; Berkowitz, RD; Bettegowda, C; Cho, SY; Conklin, JJ; Gelb, J; McLeroth, P; Mont, MA; Petit, C; Pomper, MG; Saha, S; Siegel, BA; Spaltro, J; Stabin, MG; Zhang, HH; Zhang, XM, 2016) | 0.43 |
| " There are marked differences in drug dosing and scheduling depending on the protocols when treating AML patients with AraC." | ( Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients. Berda-Haddad, Y; Ciccolini, J; Costello, R; Donnette, M; Fanciullino, R; Farnault, L; Giocanti, M; Hau, LTT; Lacarelle, B; Ouafik, L; Solas, C; Venton, G, 2019) | 0.51 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| N-glycosyl compound | A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a nitrogen atom, thus creating a C-N bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID587231 | Cytotoxicity against human MCF7 cells assessed as cell growth inhibition at 20 ug/ml after 72 hrs by sulforhodamine B assay | 2011 | Journal of natural products, Feb-25, Volume: 74, Issue:2 | Bioactive compounds from the fern Lepisorus contortus. |
| AID475458 | Antiviral activity against HIV1 3B infected human CEM cells assessed as inhibition of syncytia formation after 4 days | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID475470 | Antiviral activity against HSV1 KOS assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID1136033 | Inhibition of Herpesvirus 1 pyrimidine 2'-deoxyribonucleoside kinase by double reciprocal plot analysis in presence of thymidine | 1979 | Journal of medicinal chemistry, Oct, Volume: 22, Issue:10 | Antiviral and antineoplastic activities of pyrimidine arabinosyl nucleosides and their 5'-amino derivatives. |
| AID1123259 | Cytotoxicity against primary rabbit kidney cells assessed as change in cell morphology | 1979 | Journal of medicinal chemistry, Mar, Volume: 22, Issue:3 | 5-Substituted uracil arabinonucleosides as potential antiviral agents. |
| AID475463 | Cytostatic activity mouse L1210 cells | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID1123319 | Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil. |
| AID475478 | Antiviral activity against Sindbis virus assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID587227 | Inhibition of ovine COX1 assessed as PGE2 formation at 10 ug/ml by LC-MS-MS analysis | 2011 | Journal of natural products, Feb-25, Volume: 74, Issue:2 | Bioactive compounds from the fern Lepisorus contortus. |
| AID475477 | Antiviral activity against Reovirus 1 assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID587230 | Cytotoxicity against mouse Hepa-1c1c7 cells assessed as cell growth inhibition at 20 ug/ml after 72 hrs by sulforhodamine B assay | 2011 | Journal of natural products, Feb-25, Volume: 74, Issue:2 | Bioactive compounds from the fern Lepisorus contortus. |
| AID475474 | Antiviral activity against Respiratory syncytial virus Long assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID1123324 | Antiviral activity against Herpes simplex virus-2 196 infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil. |
| AID1123322 | Antiviral activity against Herpes simplex virus-1 KOS infected in human skin fibroblast cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil. |
| AID587226 | Inhibition of NO production in mouse RAW264.7 cells at 20 ug/ml after 30 mins by Griess assay | 2011 | Journal of natural products, Feb-25, Volume: 74, Issue:2 | Bioactive compounds from the fern Lepisorus contortus. |
| AID475479 | Antiviral activity against Punta Toro virus assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID1123258 | Antiviral activity against HSV1 KOS infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity | 1979 | Journal of medicinal chemistry, Mar, Volume: 22, Issue:3 | 5-Substituted uracil arabinonucleosides as potential antiviral agents. |
| AID475457 | Antiviral activity against HIV2 infected human CEM cells assessed as inhibition of syncytia formation after 4 days | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID475464 | Cytostatic activity human CEM cells | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID1123256 | Antiviral activity against Vesicular stomatitis virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity | 1979 | Journal of medicinal chemistry, Mar, Volume: 22, Issue:3 | 5-Substituted uracil arabinonucleosides as potential antiviral agents. |
| AID1879226 | Antiviral activity against HCV by replicon assay | 2022 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 61 | Design, chemical synthesis and antiviral evaluation of 2'-deoxy-2'-fluoro-2'-C-methyl-4'-thionucleosides. |
| AID475459 | Cytostatic activity against human NB4 cells | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID475472 | Antiviral activity against Herpes simplex virus2 G assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID1123257 | Antiviral activity against Vaccinia virus infected in human skin fibroblasts assessed as inhibition of virus-induced cytopathogenicity | 1979 | Journal of medicinal chemistry, Mar, Volume: 22, Issue:3 | 5-Substituted uracil arabinonucleosides as potential antiviral agents. |
| AID475461 | Cytostatic activity human KG1 cells | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID475471 | Antiviral activity against thymidine kinase deficient acyclovir resistant HSV1 KOS assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID475480 | Antiviral activity against influenza A virus H1N1 assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID587228 | Inhibition of human COX2 assessed as PGE2 formation at 10 ug/ml by LC-MS-MS analysis | 2011 | Journal of natural products, Feb-25, Volume: 74, Issue:2 | Bioactive compounds from the fern Lepisorus contortus. |
| AID475481 | Antiviral activity against influenza A virus H3N2 assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID475462 | Cytostatic activity human U937 cells | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID1123320 | Antiviral activity against Vaccinia virus infected in human skin fibroblast cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil. |
| AID1123260 | Cytotoxicity against human skin fibroblasts assessed as change in cell morphology | 1979 | Journal of medicinal chemistry, Mar, Volume: 22, Issue:3 | 5-Substituted uracil arabinonucleosides as potential antiviral agents. |
| AID475475 | Antiviral activity against Vesicular stomatitis virus assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID1123326 | Antimetabolic activity against primary rabbit kidney cells assessed as inhibition of [2-14C]dUrd incorporation into DNA after 16 hrs | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil. |
| AID1123321 | Antiviral activity against Herpes simplex virus-1 KOS infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil. |
| AID475473 | Antiviral activity against Vaccinia virus lederle assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID475482 | Antiviral activity against Human parainfluenza virus 3 assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID1123325 | Antimetabolic activity against primary rabbit kidney cells assessed as inhibition of [methyl-3H]dThd incorporation into DNA after 16 hrs | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil. |
| AID1123255 | Antiviral activity against HSV1 KOS infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity | 1979 | Journal of medicinal chemistry, Mar, Volume: 22, Issue:3 | 5-Substituted uracil arabinonucleosides as potential antiviral agents. |
| AID1123254 | Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity | 1979 | Journal of medicinal chemistry, Mar, Volume: 22, Issue:3 | 5-Substituted uracil arabinonucleosides as potential antiviral agents. |
| AID1123318 | Antiviral activity against Vesicular stomatitis virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil. |
| AID1123323 | Antiviral activity against Herpes simplex virus-2 LYONS infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 to 3 days after virus infection | 1979 | Journal of medicinal chemistry, Jun, Volume: 22, Issue:6 | Synthesis and antiviral activities of arabinofuranosyl-5-ethylpyrimidine nucleosides. Selective antiherpes activity of 1-(beta-D-arabinofuranosyl)-5-ethyluracil. |
| AID475460 | Cytostatic activity against human HL60 cells | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| AID475476 | Antiviral activity against Coxsackievirus B4 assessed as inhibition of virus-induced cytopathicity by cell based assay | 2010 | Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7 | Phosphoramidates of 2'-beta-D-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 128 (21.84) | 18.7374 |
| 1990's | 197 (33.62) | 18.2507 |
| 2000's | 163 (27.82) | 29.6817 |
| 2010's | 93 (15.87) | 24.3611 |
| 2020's | 5 (0.85) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Trials | 43 (7.14%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Reviews | 51 (8.47%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Case Studies | 22 (3.65%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 1 (0.17%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| Other | 485 (80.56%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||